-This study aimed to compare the Varian portal dosimetry system and the ImatriXX 2-D array system of IBA dosimetry for IMRT and Rapid arc patient specific quality assurance (QA). Fifteen cases of IMRT and fifteen cases of Rapid arc plans were selected for the patient specific QA study using portal dosimetry and ImatriXX 2-D array system. Planar dose comparison was carried out with gamma criteria of 3% -3 mm {dose difference and distance-to-agreement (DTA)}. For portal dosimetry system area gamma, average gamma and maximum gamma were analyzed and for the ImatriXX 2-D array system, the % of pixels passing the 3%-3mm gamma was chosen. In case of IMRT, the portal dosimetry mean values of area gamma, average gamma and maximum gamma were 1.01, 0.48 and 1.72 with standard deviation values of 0.38, 0.05 and 0.20 and for Rapid arc the corresponding values were 2.01, 0.48 and 1.72 with standard deviation of 0.54, 0.07 and 0.29. With the ImatriXX 2-D array system, on an average 99.22% of the pixels passed the criteria of 3%-3 mm with standard deviation of 0.58 for IMRT. For rapid arc, the average value was 97.14% with a standard deviation of 1.26. The results showed that both the systems can be use for patient specific QA measurements for IMRT and rapid arc. Portal dosimetry as well as ImatriXX measurements showed significant difference in gamma results of IMRT vs. rapid arc with pvalue less than 0.05. Compared to ImatriXX 2-D array system, the portal dosimetry values were more consistent. The portal dosimetry QA is less time consuming and in case of IMRT individual field verification is easier compared to ImatriXX 2-D array system.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.